OBJE<..i1VE: To review the clinical data detailing the use of respiratory syncytial virus immune globulin intravenous (RSV-IGIV) in infants and children.
This article is approved for continuing education credit.
confined to the upper respiratory tract accounts for 60% of infections, and 40% of these infections manifest as bronchiolitis or pneumonia. 4 Although the overall mortality of RSV disease is low, certain groups of infants and children are at higher risk for significant morbidity or death due to RSV disease. These groups include infants who are less than 6 months' postnatal age and were born prematurely, those with underlying pulmonary or cardiac disease, and infants with immunodeficiency states. 2 Until recently, RSV treatment consisted of supportive care or the use of inhaled ribavirin. s Clinical trials examining the efficacy of inhaled ribavirin have shown only modest improvement of RSV disease with no clear reduction in hospital days or intensive care unit (lCU) admissions. 6 Currently, a vaccine for RSV is not available. Prophylactic and treatment strategies, such as nonspecific immunoglobulins, have not been shown to be effective in preventing RSV disease or to significantly lessen the symptomatic course of RSV bronchiolitis or pneumonia. 7 Although nonspecific immunoglobulins contain antibodies to RSY, large doses of these products administered at frequent intervals are required for protection against RSV disease. s Stated another way, the serum neutralizing titers to RSV of nonspecific products were not adequate to prevent the disease or reduce the incidence of severe RSV. 7 The development of an immunoglobulin product with specific antibodies for RSV has been the focus of much research. In December 1995, the Blood Products Advisory Committee of the Food and Drug Administration (FDA) approved respiratory syncytial virus immune globulin intravenous (RSV-IGIV) for marketing.
This article reviews RSY-IGIV pharmaceutics, pharmacokinetics, administration, adverse effects, and the current clinical data concerning the efficacy and safety of RSY-IGIV in infants and children for the prophylaxis of RSV disease. prevention of sepsis, Kawasaki disease, and primary and secondary immunodeficiency syndromes. Standard human serum globulin is available in two forms, intramuscular immune globulin or intravenous immune globulin (IVIG).9 These compounds provide passive immunity by increasing immunoglobulin concentrations. Administration of antibodies increases the antibody-antigen interaction and provides short-lived protection against or modification of the disease process. The use of immunoglobulins in infectious disease has met with variable success due in part to the immunoglobulin titer of these preparations. Different lots of IVIG have various concentrations of immunoglobulin (lg) G, which can exhibit varying degrees of effectiveness.?
Data from infants with RSV disease suggested that the severity of RSV pneumonia and concentrations of neutralizing titer antibody were inversely related. lo In a retrospective study, Parrott et aLII noted that patients with RSV neutralization antibody titers of I:300 to 1:400 were protected against RSY. Successful prophylaxis against RSV in rats and monkeys led to an examination of IVIG use in young children. IVIG was given to infants and children with established RSV disease in a randomized, double-blind, controlled trial. 12 Although the researchers observed significant reductions in nasal virus (p < 0.01) and improvement in oxygenation (p < 0.05), no significant decrease in mean duration of hospitalization occurred in the treatment group compared with the control group.
Other trials with standard IVIG reported a trend toward less hospitalization and less severe disease in treatment subjects compared with controls.?, 13 Results from these studies demonstrated the safety and feasibility of IVIG use for RSV disease, but peak neutralizing antibody concentrations were too low to provide protection against RSV disease. Subsequent to IVIG trials, an immunoglobulin product (RSV-IGIV) was developed that contained high serum neutralizing antibody titer by using plasma obtained from donors who exhibited high RSV neutralizing antibody titer.
Formulation ofRSV-IGIV
RSV-IGIV is a pooled sample ofIgG antibodies that contains a high concentration of neutralizing and protective antibodies specific for RSy '14 In vitro testing has shown that RSV-IGIV is active against the clinically important strains of RSV subgroup A and subgroup B. RSV-IGIV is a liquid preparation with a solvent detergent added to decrease the likelihood of transmission of bloodborne pathogens. ls To purify the product, the Cohn-On-cleyl6 cold ethanol precipitation procedure is used. Each milliliter of RSV-IGIV contains IgG 50 ± 10 mg (SD) with traces of IgA and IgM, sucrose 50 mg, and human albumin 10 mg. The solution is colorless, translucent, and contains 20-30 mEq of sodium per liter. 16 Pharmacokinetics RSV-IGIV doses of750 mg/kg attained trough geometric mean serum RSV neutralization titers of 1:297 ± 38 (SEM) I month after the first infusion. Experts expect that protection against RSV infection is obtained with titers of I :200 to I :400. 9 One month after the second, third, and fourth monthly infusion of RSV-IGIV 750 mg/kg, titers were 1:477 ± 85,1:490 ± 61, and 1:429 ± 23, respectively. After administration, the half-life of serum RSV neutralizing antibodies is 22-28 days}?
Clinical Studies
Clinical studies of RSV-IGN administration in neonates and infants have focused on the prophylaxis l8 . 20 or treatment 21 of RSV disease. A multicenter, double-blind, randomized, placebo-controlled triaP8 was conducted using monthly doses of 750 mg/kg (15 mUkg; high dose) or ISO mg/kg (3 mL/kg; low dose) of RSV-IGIV, or a volumeidentical albumin infusion (control). Over a 3-year period, 81 infants received the high dose, 79 received the low dose, and 89 received the control. Patients were premature (n =21, 18, and 21 in the high-dose, low-dose, and control groups, respectively), had bronchopulmonary dysplasia (BPD) (n =37, 28 , and 37 in the high-dose, low-dose, and control groups, respectively), or had congenital heart disease (CHD) (n = 23, 33, and 31 in the high-dose, lowdose, and control groups, respectively). The number of patients with prematurity, BPD, or CHD did not differ significantly among groups. Additionally, patients who were premature ($35 wk gestation) were less than 6 months postnatal age; all patients were younger than 24 months chronological age.
Patients who received RSV-IGIV 750 mg/kg had a significant reduction in number of hospitalizations and hospital days compared with placebo (p = 0.05). Furthermore, the high-dose group had fewer admissions to the ICU and fewer days in the ICU compared with the placebo group. Patients in the high-dose treatment group had I (1.2%) admission to the ICU versus 6 (6.7%) in the placebo group (NS) and remained in ICU for I day/patient group versus 34 days/patient group (p =0.05), respectively. Patients who received low-dose RSV-IGIV experienced fewer admissions to the ICU (p = 0.03) and fewer days in the ICU (p = 0.03) compared with the placebo group. However, the high-dose and control groups did not differ significantly in ICU admissions. 18 One possible explanation for this is that the high-dose group had more premature infants than the low-dose group. Premature infants are more likely to require ICU admission due to RSV disease than are infants not born prematurely. 22 The high-dose group experienced fewer mild lower respiratory tract infections of any cause and moderate-to-severe RSV lower respiratory tract infections compared with the placebo group (21 vs. 44 and 3 vs. 12, respectively; p = 0.007 and p =0.02, respectively). Mild respiratory tract infections were defined as a value of 2 or more on a respiratory severity score scale (Table I ). There were no significant differences in the incidence of any category of respiratory illness in the low-dose RSV-IGIV group compared with the control groUp. 18 In the subsequent RSV season, 210 of 249 (84%) of the study patients were followed for RSV disease and hospitalization. Depending on the presence of RSV in the com- (Table I) , infants in the treatment group who acquired an RSV respiratory infection had a milder clinical course compared with control infants (1.5 ± 0.26 vs. 2.63 ± 0.31, respectively; p = 0.02). The number of hospital days and number of ICU days in the treatment group compared with the placebo group did not differ significantly. It is important to note that in the original multicenter trial there was a significant difference (p = 0.02) between the high-dose and placebo groups when days in the hospital were compared. 18 This reanalysis led the authors to recommend that RSV-IGIV be considered for any infant born at less than 32 weeks' gestation and younger than 6 months' postnatal age at the onset of the RSV season. RSV-IGIV should also be considered for infants and children younger than 24 months old with BPD and those who have required supplemental oxygen less than 6 months before the onset of RSV season. '8 Another multicenter trial (PREVENT)19 examined the use of high-dose (750 mglkg) RSV-IGIV in 510 patients born prematurely (±36 wk gestation) or had BPD. Complete information is not accessible as the results were available only in abstract form at the time of this writing. The infants (mean age 5.8 mo, range 0.1-23.8) were randomized in a double-blind fashion (260 placebo, 250 RSV-IGIV) at 54 centers in the US. Patients were eligible for the study if they required oxygen within 6 months prior to randomization and received monthly infusions of RSV-IGIV during RSV season. Eighty-five percent of the infants received a full course oftherapy (4-5 infusions). Patients who received RSV-IGIV had a 46% reduction in hospital days compared with those who received placebo (p =0.007). In addition, there was a 41 % reduction in hospitalization and 53% reduction in total hospital days in the RSV-IGIV group compared with the placebo group (p = 0.047 and p = 0.045, respectively). The authors concluded that RSV-IGIV was safe and effective for infants «24 mo) with BPD and/or a history of prematurity.
Two additional studies using RSV-IGIV have been recently published in abstract form. The first (MI-RSV-9001)21 investigated the efficacy and safety of higher-dose RSV-IGIV (1500 mglkg) in patients without comorbidities (i.e., prematurity, BPD, CHD), for the treatment of RSV disease. Forty-six children received RSV-IGIV and 52 received placebo in this double-blind, randomized study. Although not statistically significant, the treatment group had fewer hospital days, ICU admissions, and mechanical ventilation days than the placebo group. Patients with higher respiratory scores (~2.5) (Table I) benefited more from RSV-IGIV administration than did children who were not as sick.
A double-blind investigation studied the use of RSV-IGIV for prophylaxis ofRSV in 416 children with cyanotic and acyanotic CHD.20 Patients were randomized to receive RSV-IGIV 750 mglkg (n =202) or placebo (n = 214). The authors observed no significant difference in hospitalizations, ICU admissions, or mechanical ventilation days between the two groups. In infants younger than 6 months of age, a trend toward fewer hospital admissions in the treatment group was noted (18% vs. 10%; NS). RSV-IGIV was not statistically efficacious in patients with CHD.
Surgically related severe events and deaths occurred more often in the treatment group of patients with cyanotic CHD (22/78 [28.2%] vs. 4/47 [8.5%]; P =0.01, and 5 vs. 0, respectively; no p value reported). Even though these events did not appear to be related to RSV-IGIV administration, the authors concluded that the use of RSV-IGIV in patients with cyanotic CHD should be avoided until the observed surgical events can be explained. 20 Subsequent to the publication of the Groothuis et al. multicenter trial in 1993,'8 RSV-IGIV was reviewed by the Blood Products Advisory Committee of the FDA. The committee unanimously rejected the licensing application. Representatives from the FDA then documented their concerns about this trial. The concerns included the randomization method used at the study sites, intention-to-treat documentation, consistency of the treatment effect across sites, and deaths in treatment groupS. 24 The FDA representatives stated that the researchers did not adequately control for bias in the randomization methodology and all patients were not adequately followed for the intention-to-treat analysis. 24 The adverse effects associated with RSV-IGIV have been mild and reversible. In general, adverse effects have occurred in 1-3% of patients in treatment groupS. 18, 19 Those that occurred in more than 1% of the patients who received RSV-IGIV included fever (6%), respiratory distress (2%), vomiting (2%), and wheezing (2%).18.21 Adverse reactions that occurred in 1% of the treatment group patients included diarrhea, rales, fluid overload, tachycardia, rash, hypertension, hypoxia, tachypnea, gastroenteritis, and injection site inflammation. 16 ,18 Less commonly occurring adverse effects included edema, pallor, hypotension, heart murmur, gagging, sleepiness, cough, rhinorrhea, eczema, cold and clammy skin, and conjunctival hemorrhage. 16 Previous studies have noted higher mortality and adverse effect rates in children with cyanotic CHI) who have received RSV-IGIV. 18 ,20 In one ofthese trials a temporal relationship of adverse effects and administration of RSV-IGIV was not established. 18 RSV-IGIV should not be used tion-to-treat analysis, the high-dose group still had significantly fewer hospitalizations with RSV than the control group (8/92 vs. 10/90 patients, respectively; p =0.03). Additionally, the high-dose group had a 59% reduction in the number of hospital days and a 97% reduction in days in the ICU, compared with the placebo group (p = 0.03). A separate intention-to-treat analysis included 257 randomized, eligible, enrolled children and demonstrated a 65% reduction in hospitalizations due to RSV in the high-dose group compared with the control group (p = 0.01).
Consistency of effect across study sites was questioned due to the statistically different outcomes in treatment groups versus the control group in one center and not the others. The FDA representatives concluded that when excluding the site with the greatest degree of efficacy reported there was no significant difference in outcome variables in the treatment versus control groupS. 24 The authors pointed out that patients in two of five centers did not have patients with RSV disease severe enough to demonstrate a significant reduction in severity or incidence of the disease. Furthermore, they stated that three sites had reduction in lower respiratory tract RSV infections, two sites had reduction in mean severity of infections, and four sites had fewer hospitalizations and hospital days due to RSV. Although these differences are not significant if each center is considered separately, this study was designed to have an overall power of 80% and was not intended to reach significance at individual sites or when the site with the highest efficacy was excluded. 25 Finally, the six children who died in the study were assigned to treatment groups and, although that trend is not significant, it is disturbing. Analysis of the study deaths by two independent pediatric cardiologists showed no relationship to the study drug infusion and death in five of these patients, all of whom had CHD. The sixth patient, who had BPD, experienced multiple episodes of respiratory failure, one of which was associated with RSV-IOIV infusion. 25 
Adverse Effects
• in patients with cyanotic heart disease due to the medication's lack of statistical efficacy and the observed adverse effects in this subset of infants. 20 Administration RSV-IGIV is administered as a single monthly infusion of 750 mglkg (15 mlJkg) beginning in September or October and continued for a total of 5 doses.1 8 The product is not diluted and the rate of infusion is 1.5 mLlkglh for the first 15 minutes. If no adverse effects are noted, the infusion rate can be increased to 3.0 mLlkglh for the next 15 minutes and then to 6.0 mLlkglh for the remainder of the infusion. 16 Slower rates of infusion can be used in children who are volume sensitive, such as those with BPD or prematurity.18 RSV-IGIV should be given in a separate intravenous line from any other medication, but it can be given in an existing line that contains dextrose 2.5%, 5%, 10%, or 20% in water, with or without NaCl 0.9%. The product should not be diluted any more than 1:2 if RSV-IGIV is coadrninistered with the above solutions. 16
Therapeutic and Economic Issues
There is no alternative prophylactic pharmacotherapy for RSV-IGIV. Traditional therapy for RSV disease has focused on supportive care and the use of~-agonists, steroids, and ribavirin for selected patients. 6 Concerns have been raised regarding the apparent lack of efficacy of these agents and the high cost of administration of ribavirin. 5 ,6,26,27 Average wholesale price for RSV-IGIV 2.5 g is $599. To maximize use of the vial, several children should be given the product at specific times during the RSV season. A five-dose regimen has been estimated to cost $5135. 19 This cost takes into account the drug and administration costs and assumes that doses 1 and 2 are given while the child is in the hospital and doses 3-5 are given on an outpatient basis. The cost of one hospitalization for RSV disease has been estimated to be between $7067 and $70166. 28 
,29
A recent article 30 presents a recommendation for an RSV-IGIV analysis model. Using administration costs and avoidance of hospital admission and reduction in stay, it is suggested that the cost-impact of RSV-IOIV can be determined. Although such an analysis is appropriate and helpful in determining hospital cost avoidance, other costs (indirect and ambulatory) of RSV were not considered (e.g., reduction in otitis media, reduction in travel costs, work missed, baby-sitter fees). We found these costs to be quite significant in the ambulatory setting for a common pediatric disorder such as otitis media. 31 RSV-IGIV may not only provide cost avoidance in the hospital setting, but also decrease costs of ambulatory management of the disease through prevention.
Hay et al. 32 found that the cost of RSV-IGIV prophylaxis, per year of life saved, ranged from $10000 to $32 000. The authors concluded that RSV-IGIV therapy displayed cost-effectiveness similar to that of other treatment interventions such as antihypertensive therapy, neonatal intensive care, and cholecystectomy.
Quality-of-life issues must also be accounted for. RSV disease is a significant psychological burden to the infant and the family. RSV disease can cause significant morbidity itself, and some data suggest that individuals who have a family history of asthma or atopy and contract RSV may be at higher risk for asthma. 33
The interactions of vaccines and immunoglobulin products may increase the costs associated with the use of RSV-IGIY. In the case of an inactivated antigen vaccine (e.g., hepatitis B), the Advisory Committee on Immunization Practices does not recommend an interval between the vaccine and immunoglobulin product administration, although the vaccine and immunoglobulin should be administered at different anatomic sites. 34 However, a booster dose may be considered in the case of diphtheria, pertussis, acellular pertussis, tetanus, Haemophilus influenza b, and oral polio 3-4 months after the last RSV-IGIV infusion of the season. t6 Depending on the vaccine, nationwide immunization levels are approximately 70-80%.35 Given this fact, it is probably unlikely that a child would receive a booster dose of vaccine. The immune response to yellow fever and oral polio virus vaccines has not been reported to be affected by immunoglobulin products. 36 It is recommended that if there is simultaneous administration of measles, mumps, rubella (MMR), or monovalent measles vaccine with RSV-IGIV, the patient should be revaccinated or tested for seroconversion. 34 The period before revaccination varies from 3 to 11 months, depending on the dose of immunoglobulin given. If the MMR vaccine is given before RSV-IGIV, a lO-month separation period between the two products is recommended. 34 The overall cost of RSV-IGIV therapy probably would increase if a failure of vaccination occurs due to decreased immune response.
Finally, the issue of availability may be of concern. If RSV-IGIV is used in a majority of newborn and pediatric units across the US, a product shortage may occur.
Summary
Therapy for RSV pneumonia or bronchiolitis currently consists of supportive care,~-agonists, steroids, or ribavirin for selected individuals. RSV-IGIV offers effective passive immunity against RSV in children who are premature, have BPD, and are less than 24 months' postnatal age. Pharmacoeconomic data are lacking, but it appears the use of RSV-IGIV would result in cost avoidance if used for prophylaxis of RSV disease in these subgroups. Existing clinical information has shown that RSV-IGIV decreases hospital admissions, hospital stay, and ICU admissions from RSV disease in infants and children.
Cautious use of RSV-IGIV in infants with certain forms of CHD seems warranted due to the lack of data documenting significant reduction in hospitalizations and hospital stay. Until more data become available, RSV-IGIV use should be avoided in patients with cyanotic CHD. Although clinical data are lacking, patients who are immunosuppressed may also benefit from RSV-IGIV.
RSV-IGIV offers a significant advantage over drugs such as ribavirin that are primarily used for supportive care or treatment. Trials with intramuscular monoclonal RSV products are ongoing and may provide more convenient, dependable, passive immunity to RSY. Until then, except RSV Immune Globulin for RSV-IGIV, no drug product provides reliable passive immunity to RSV disease.
Future studies may provide evidence that more severely premature infants or infants with oxygen requirement may benefit more from RSV-IGIV than older, well infants and children. As that data become available, guidelines or recommendations for use should be reconsidered and the patient population selection criteria should be further de- SINTESIS: IGIV-VSR es un producto de inmunoglobulina con tftulos neutralizantes de suero contra el VSR. Se ha demostrado que reduce la estadfa en el hospital, admisiones, admisiones a unidades de cuidado intensivo y los dfas en ventilacion mecanica de infantes y niiios con pulmonfa por VSR 0 bronquiolitis, que son menores de 24 meses y son prematuros, 0 que tienen displasia broncopulmonar. IGIV-VSR es bien tolerada en infantes y niiios. 
